0
USD
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Primary Progressive Multiple Sclerosis- Market Insight, Epidemiology and Market Forecast - 2028
Published Date: March 2019
|
Report Code: DELV-Mark-026
Home | Category |Health |Pharmacy |Drugs & Medications
Primary Progressive Multiple Sclerosis Market Insight Epidemiology and Market Forecast 2

Primary Progressive Multiple Sclerosis- Market Insight, Epidemiology and Market Forecast - 2028

Code: DELV-Mark-026
Report
March 2019
100 Pages
Delveinsight
Region: Africa, Asia Pacific, Europe, Middle East, North America, South America,
Description
Table of Content
Tables & Figures

DelveInsight's "Primary Progressive Multiple Sclerosis (PPMS) - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Primary Progressive Multiple Sclerosis (PPMS) epidemiology and market outlook for the 7MM.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Primary Progressive Multiple Sclerosis (PPMS) Understanding and Treatment Algorithm
The market report provides the overview of the Primary Progressive Multiple Sclerosis (PPMS) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Primary Progressive Multiple Sclerosis (PPMS) Epidemiology
The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Primary Progressive Multiple Sclerosis (PPMS) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Primary Progressive Multiple Sclerosis (PPMS) Product Profiles & Analysis
The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Primary Progressive Multiple Sclerosis (PPMS) Market Outlook
The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Primary Progressive Multiple Sclerosis (PPMS) market.

Primary Progressive Multiple Sclerosis (PPMS) Market Share by Therapies
This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Primary Progressive Multiple Sclerosis (PPMS) Report Insights
• Patient Population in Primary Progressive Multiple Sclerosis (PPMS)
• Therapeutic Approaches in Primary Progressive Multiple Sclerosis (PPMS)
• Primary Progressive Multiple Sclerosis (PPMS) Pipeline Analysis
• Primary Progressive Multiple Sclerosis (PPMS) Market Size and Trends
• Primary Progressive Multiple Sclerosis (PPMS) Market Opportunities
• Impact of upcoming Therapies in Primary Progressive Multiple Sclerosis (PPMS)

Primary Progressive Multiple Sclerosis (PPMS) Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Primary Progressive Multiple Sclerosis (PPMS) Report Assessment
• Current Treatment Practices in Primary Progressive Multiple Sclerosis (PPMS)
• Unmet Needs in Primary Progressive Multiple Sclerosis (PPMS)
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• The report will help to develop Business Strategies by understanding the trends shaping and driving the Primary Progressive Multiple Sclerosis (PPMS) market
• Organize sales and marketing efforts by identifying the best opportunities for Primary Progressive Multiple Sclerosis (PPMS) market
• To understand the future market competition in the Primary Progressive Multiple Sclerosis (PPMS) market.

1. Report Introduction
2. Primary Progressive Multiple Sclerosis (PPMS) Market Overview at a Glance
2.1. Market Share Distribution of Primary Progressive Multiple Sclerosis (PPMS) in 2016
2.2. Market Share Distribution of Primary Progressive Multiple Sclerosis (PPMS) in 2028
3. Disease Background and Overview: Primary Progressive Multiple Sclerosis (PPMS)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Primary Progressive Multiple Sclerosis (PPMS) in 7MM
4.3. Total Prevalent Patient Population of Primary Progressive Multiple Sclerosis (PPMS) in 7MM – By Countries
5. Epidemiology of Primary Progressive Multiple Sclerosis (PPMS) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.1.3. Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.1.4. Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.1.5. Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.1.6. Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.4.3. Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.4.4. Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.4.5. Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.4.6. Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.5.3. Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.5.4. Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.5.5. Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.5.6. Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.6.3. Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.6.4. Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.6.5. Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.6.6. Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.7.3. Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.7.4. Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.7.5. Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.7.6. Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.8.3. Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.8.4. Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.8.5. Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.8.6. Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.9.3. Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.9.4. Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.9.5. Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.9.6. Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS)
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Primary Progressive Multiple Sclerosis (PPMS)
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Primary Progressive Multiple Sclerosis (PPMS)
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Primary Progressive Multiple Sclerosis (PPMS) : 7MM Market Analysis
12.1. 7MM Market Size of Primary Progressive Multiple Sclerosis (PPMS)
12.2. 7MM Percentage Share of drugs marketed for Primary Progressive Multiple Sclerosis (PPMS)
12.3. 7MM Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Products
13. Primary Progressive Multiple Sclerosis (PPMS) : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Primary Progressive Multiple Sclerosis (PPMS) in United States
13.1.2. Percentage Share of drugs marketed for Primary Progressive Multiple Sclerosis (PPMS) in United States
13.1.3. Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Primary Progressive Multiple Sclerosis (PPMS) in Germany
13.2.1.2. Percentage Share of drugs marketed for Primary Progressive Multiple Sclerosis (PPMS) in Germany
13.2.1.3. Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Primary Progressive Multiple Sclerosis (PPMS) in France
13.2.2.2. Percentage Share of drugs marketed for Primary Progressive Multiple Sclerosis (PPMS) in France
13.2.2.3. Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Primary Progressive Multiple Sclerosis (PPMS) in Italy
13.2.3.2. Percentage Share of drugs marketed for Primary Progressive Multiple Sclerosis (PPMS) in Italy
13.2.3.3. Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Primary Progressive Multiple Sclerosis (PPMS) in Spain
13.2.4.2. Percentage Share of drugs marketed for Primary Progressive Multiple Sclerosis (PPMS) in Spain
13.2.4.3. Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Primary Progressive Multiple Sclerosis (PPMS) in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Primary Progressive Multiple Sclerosis (PPMS) in United Kingdom
13.2.5.3. Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Primary Progressive Multiple Sclerosis (PPMS) in Japan
13.3.2. Percentage Share of drugs marketed for Primary Progressive Multiple Sclerosis (PPMS) in Japan
13.3.3. Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

*Indication Specific

LIST OF TABLES :

Table 1: Total Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)
Table 7: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028)
Table 11: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028)
Table 12: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028)
Table 14: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028)
Table 15: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028)
Table 16: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028)
Table 17: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028)
Table 21: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028)
Table 22: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028)
Table 26: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028)
Table 27: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028)
Table 30: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028)
Table 31: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028)
Table 32: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028)
Table 36: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028)
Table 37: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Table 42:7MM- Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Table 45: United States-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Table 48: Germany-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Table 51: France-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Table 54: Italy-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Table 57: Spain-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Table 60:UK-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Table 63: Japan-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)

LIST OF FIGURES :

Figure 1: Total Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)
Figure 7: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028)
Figure 12: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028)
Figure 15: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028)
Figure 16: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028)
Figure 17: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028)
Figure 22: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028)
Figure 27: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028)
Figure 31: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028)
Figure 32: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028)
Figure 37: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Figure 42:7MM- Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Figure 45: United States-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Figure 48: Germany-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Figure 51: France-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Figure 54: Italy-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Figure 57: Spain-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Figure 60:UK-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Figure 63: Japan-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)

DelveInsight's "Primary Progressive Multiple Sclerosis (PPMS) - Market Insight, Epidemiology and Market Forecast - 2028" report provides a detailed analysis of the Primary Progressive Multiple Sclerosis (PPMS) epidemiology and market outlook for the 7MM.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Primary Progressive Multiple Sclerosis (PPMS) Understanding and Treatment Algorithm
The market report provides the overview of the Primary Progressive Multiple Sclerosis (PPMS) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Primary Progressive Multiple Sclerosis (PPMS) Epidemiology
The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Primary Progressive Multiple Sclerosis (PPMS) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Primary Progressive Multiple Sclerosis (PPMS) Product Profiles & Analysis
The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Primary Progressive Multiple Sclerosis (PPMS) Market Outlook
The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Primary Progressive Multiple Sclerosis (PPMS) market.

Primary Progressive Multiple Sclerosis (PPMS) Market Share by Therapies
This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Primary Progressive Multiple Sclerosis (PPMS) Report Insights
• Patient Population in Primary Progressive Multiple Sclerosis (PPMS)
• Therapeutic Approaches in Primary Progressive Multiple Sclerosis (PPMS)
• Primary Progressive Multiple Sclerosis (PPMS) Pipeline Analysis
• Primary Progressive Multiple Sclerosis (PPMS) Market Size and Trends
• Primary Progressive Multiple Sclerosis (PPMS) Market Opportunities
• Impact of upcoming Therapies in Primary Progressive Multiple Sclerosis (PPMS)

Primary Progressive Multiple Sclerosis (PPMS) Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Primary Progressive Multiple Sclerosis (PPMS) Report Assessment
• Current Treatment Practices in Primary Progressive Multiple Sclerosis (PPMS)
• Unmet Needs in Primary Progressive Multiple Sclerosis (PPMS)
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• The report will help to develop Business Strategies by understanding the trends shaping and driving the Primary Progressive Multiple Sclerosis (PPMS) market
• Organize sales and marketing efforts by identifying the best opportunities for Primary Progressive Multiple Sclerosis (PPMS) market
• To understand the future market competition in the Primary Progressive Multiple Sclerosis (PPMS) market.

Read More

1. Report Introduction
2. Primary Progressive Multiple Sclerosis (PPMS) Market Overview at a Glance
2.1. Market Share Distribution of Primary Progressive Multiple Sclerosis (PPMS) in 2016
2.2. Market Share Distribution of Primary Progressive Multiple Sclerosis (PPMS) in 2028
3. Disease Background and Overview: Primary Progressive Multiple Sclerosis (PPMS)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Primary Progressive Multiple Sclerosis (PPMS) in 7MM
4.3. Total Prevalent Patient Population of Primary Progressive Multiple Sclerosis (PPMS) in 7MM – By Countries
5. Epidemiology of Primary Progressive Multiple Sclerosis (PPMS) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.1.3. Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.1.4. Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.1.5. Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.1.6. Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.4.3. Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.4.4. Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.4.5. Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.4.6. Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.5.3. Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.5.4. Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.5.5. Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.5.6. Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.6.3. Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.6.4. Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.6.5. Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.6.6. Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.7.3. Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.7.4. Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.7.5. Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.7.6. Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.8.3. Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.8.4. Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.8.5. Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.8.6. Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.9.3. Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.9.4. Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) *
5.9.5. Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS)
5.9.6. Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS)
6. Current Treatment & Medical practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Unmet Needs of the Primary Progressive Multiple Sclerosis (PPMS)
8. Marketed Therapies
8.1. Drug A: Company 1
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company 2
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. Pipeline Therapies – At a glance
10. Key Cross Competition
11. Emerging Therapies for Primary Progressive Multiple Sclerosis (PPMS)
11.1. Drug C: Company 3
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company 4
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. Primary Progressive Multiple Sclerosis (PPMS) : 7MM Market Analysis
12.1. 7MM Market Size of Primary Progressive Multiple Sclerosis (PPMS)
12.2. 7MM Percentage Share of drugs marketed for Primary Progressive Multiple Sclerosis (PPMS)
12.3. 7MM Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Products
13. Primary Progressive Multiple Sclerosis (PPMS) : Country-Wise Market Analysis
13.1. United States
13.1.1. Market Size of Primary Progressive Multiple Sclerosis (PPMS) in United States
13.1.2. Percentage Share of drugs marketed for Primary Progressive Multiple Sclerosis (PPMS) in United States
13.1.3. Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Primary Progressive Multiple Sclerosis (PPMS) in Germany
13.2.1.2. Percentage Share of drugs marketed for Primary Progressive Multiple Sclerosis (PPMS) in Germany
13.2.1.3. Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Primary Progressive Multiple Sclerosis (PPMS) in France
13.2.2.2. Percentage Share of drugs marketed for Primary Progressive Multiple Sclerosis (PPMS) in France
13.2.2.3. Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Primary Progressive Multiple Sclerosis (PPMS) in Italy
13.2.3.2. Percentage Share of drugs marketed for Primary Progressive Multiple Sclerosis (PPMS) in Italy
13.2.3.3. Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Primary Progressive Multiple Sclerosis (PPMS) in Spain
13.2.4.2. Percentage Share of drugs marketed for Primary Progressive Multiple Sclerosis (PPMS) in Spain
13.2.4.3. Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Primary Progressive Multiple Sclerosis (PPMS) in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Primary Progressive Multiple Sclerosis (PPMS) in United Kingdom
13.2.5.3. Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Primary Progressive Multiple Sclerosis (PPMS) in Japan
13.3.2. Percentage Share of drugs marketed for Primary Progressive Multiple Sclerosis (PPMS) in Japan
13.3.3. Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. Market Drivers
15. Market Barriers
16. Appendix
17. Report Methodology
17.1. Sources
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

*Indication Specific

Read More

LIST OF TABLES :

Table 1: Total Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in 7MM
Table 2: Total Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)
Table 5: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)
Table 6: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)
Table 7: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028)
Table 11: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028)
Table 12: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028)
Table 14: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028)
Table 15: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028)
Table 16: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028)
Table 17: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028)
Table 21: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028)
Table 22: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028)
Table 26: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028)
Table 27: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028)
Table 30: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028)
Table 31: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028)
Table 32: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028)
Table 36: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028)
Table 37: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Table 42:7MM- Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Table 45: United States-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Table 48: Germany-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Table 51: France-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Table 54: Italy-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Table 57: Spain-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Table 60:UK-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Table 63: Japan-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)

LIST OF FIGURES :

Figure 1: Total Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)
Figure 6: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)
Figure 7: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028)
Figure 12: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028)
Figure 15: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028)
Figure 16: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028)
Figure 17: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028)
Figure 22: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028)
Figure 27: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028)
Figure 31: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028)
Figure 32: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028)
Figure 37: Treatable Cases of the Primary Progressive Multiple Sclerosis (PPMS) in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Figure 42:7MM- Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Figure 45: United States-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Figure 48: Germany-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Figure 51: France-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Figure 54: Italy-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Figure 57: Spain-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Figure 60:UK-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Primary Progressive Multiple Sclerosis (PPMS) in USD MM (2016-2028)
Figure 63: Japan-Market Share Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Primary Progressive Multiple Sclerosis (PPMS) by Therapies in USD MM (2016-2028)

Read More
SELECT A FORMAT
Added to Cart

Single User

Electronic (PDF)
$6250
This license allows only one user to access the PDF.

Site License

Electronic (PDF)
$12500
This license allows all the users of an enterprise residing in one location to access the PDF

Enterprise License

Electronic (PDF)
$18750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Lukasiewicz Research Network

RELATED REPORTS

Global Paclitaxel Injection Market Research Report 2021
Global Paclitaxel Injection Market Research Report 2021

120 Pages
Type: Report
Code: QYRE-Auto-5J4435
Thu Feb 04 00:00:00 UTC 2021

Add to Cart

Global Myotonic Dystrophy Medication Market Size Status and Forecast 2021 2027
Global Myotonic Dystrophy Medication Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-10R4400
Thu Feb 04 00:00:00 UTC 2021

Add to Cart

Global Acne Treatment Drug Market Size Status and Forecast 2021 2027
Global Acne Treatment Drug Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-10B4399
Thu Feb 04 00:00:00 UTC 2021

Add to Cart

Global Coronavirus Treatment Drugs Market Size Status and Forecast 2021 2027
Global Coronavirus Treatment Drugs Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-37M4166
Thu Feb 04 00:00:00 UTC 2021

Add to Cart

0 Items
X
No items in the cart.
$0.0